Matthew M. Walsh - 31 Mar 2026 Form 4 Insider Report for Organon & Co. (OGN)

Reporting relationship: Chief Financial Officer
Issuer ticker: OGN
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2026, 16:13:10 UTC
Prior SEC filing: 31 Mar 2026
Next SEC filing: 15 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Tarnetta V. Jones, as Attorney-in-Fact for Matthew M. Walsh

Key filing fact

Matthew M. Walsh filed Form 4 for Organon & Co. (OGN) on 02 Apr 2026.

Key facts

This page summarizes Matthew M. Walsh's Form 4 filing for Organon & Co. (OGN).
8 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 02 Apr 2026, 16:13.

Change

Previous filing in this sequence was filed on 31 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001269428 Primary reporting owner

WALSH MATTHEW M

Relationship: Chief Financial Officer
Address: C/O ORGANON & CO., 30 HUDSON STREET, FLOOR 33, JERSEY CITY
Signature: /s/ Tarnetta V. Jones, as Attorney-in-Fact for Matthew M. Walsh
Signature date: 02 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OGN transaction

Common Stock

Options Exercise

Transaction value
Shares: +12,047
Change %: +6.3%
Price: $0.000000^*
Shares after: 202,707
Date: 31 Mar 2026
Ownership: Direct

OGN transaction

Common Stock

Tax liability

Transaction value
Shares: -4,127
Change %: -2%
Price: $5.70^*
Shares after: 198,580
Date: 31 Mar 2026
Ownership: Direct
Footnotes: F1

OGN transaction

Common Stock

Options Exercise

Transaction value
Shares: +21,546
Change %: +11%
Price: $0.000000^*
Shares after: 220,126
Date: 31 Mar 2026
Ownership: Direct

OGN transaction

Common Stock

Tax liability

Transaction value
Shares: -7,380
Change %: -3.4%
Price: $5.70^*
Shares after: 212,746
Date: 31 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OGN transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +321,368
Change %
Price: $0.000000^*
Shares after: 321,368
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 321,368
Exercise price
Footnotes: F2

OGN transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +83,472
Change %
Price: $0.000000^*
Shares after: 83,472
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 83,472
Exercise price
Footnotes: F3

OGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -12,047
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,047
Exercise price
Footnotes: F4, F5

OGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -21,546
Change %: -33%
Price: $0.000000^*
Shares after: 43,094
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,546
Exercise price
Footnotes: F4, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

Footnote F2

On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

Footnote F3

On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

Footnote F4

Each RSU represents a contingent right to receive one share of Organon common stock.

Footnote F5

On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.

Footnote F6

On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.